Int J Cancer. 2021 Dec 18; doi: 10.1002/ijc.33912. Epub 2021 Dec 18.

Complexity against current cancer research: Are we on the wrong track?.

International journal of cancer

Yasenya Kasikci, Hinrich Gronemeyer

PMID: 34921726 DOI: 10.1002/ijc.33912

Abstract

Cancer genetics has led to major discoveries, including protooncogene and tumor-suppressor concepts, and cancer genomics generated concepts like driver and passenger genes, revealed tumor heterogeneity and clonal evolution. Reconstructing trajectories of tumorigenesis using spatial and single-cell genomics is possible. Patient stratification and prognostic parameters have been improved. Yet, despite these advances, successful translation into targeted therapies has been scarce and mostly limited to kinase inhibitors. Here, we argue that current cancer research may be on the wrong track, by considering cancer more as a "monogenic" disease, trying to extract common information from thousands of patients, while not properly considering complexity and individual diversity. We suggest to empower a systems cancer approach which reconstructs the information network that has been altered by the tumorigenic events, to analyze hierarchies and predict (druggable) key nodes that could interfere with/block the aberrant information transfer. We also argue that the interindividual variability between patients of similar cohorts is too high to extract common polygenic network information from large numbers of patients and argue in favor of an individualized approach. The analysis we propose would require a structured multinational and multidisciplinary effort, in which clinicians, and cancer, developmental, cell and computational biologists together with mathematicians and informaticians develop dynamic regulatory networks which integrate the entire information transfer in and between cells and organs in (patho)physiological conditions, revealing hierarchies and available drugs to interfere with key regulators. Based on this blueprint, the altered information transfer in individual cancers could be modeled and possible targeted (combo)therapies proposed.

© 2021 UICC.

Keywords: complexity challenge; conceptual problems in cancer genomics; information transfer; integrated network analysis

References

1. Bianconi E, Piovesan A, Facchin F, et al. An estimation of the number of cells in the human body. Ann Hum Biol. 2013;40:463-471. - PubMed
2. Borgatti SP, Mehra A, Brass DJ, Labianca G. Network analysis in the social sciences. Science. 2009;323:892-895. - PubMed
3. Kadushin C. Understanding Social Networks: Theories, Concepts and Findings. New York: Oxford University Press; 2012:251. - PubMed
4. Bullmore E, Sporns O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat Rev Neurosci. 2009;10:186-198. doi:10.1093/oso/9780198805090.001.0001 - PubMed
5. Newman M. Networks. Second Ed., Oxford: Oxford University Press; 2018. doi:10.1093/oso/9780198805090.001.0001 - PubMed
6. Bondy JA, Murty USR. Graph Theory with Applications. London: Macmillan; 1976. - PubMed
7. Zhang W, Chien J, Yong J, Kuang R. Network-based machine learning and graph theory algorithms for precision oncology. npj Precis Oncol. 2017;1:25. - PubMed
8. Kumar A, Kasikci Y, Badredine A, et al. Patient-matched analysis identifies deregulated networks in prostate cancer to guide personalized therapeutic intervention. Am J Cancer Res. 2021;11:5299-5318. - PubMed
9. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810. - PubMed
10. La GM. Connaissance est un réseau. Cah Numér. 2014;10:37-54. - PubMed
11. Nebbioso A, Tambaro FP, Dell'Aversana C, Altucci L. Cancer epigenetics: moving forward. PLoS Genet. 2018;14:e1007362. - PubMed
12. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12-27. - PubMed
13. Cholley PE, Moehlin J, Rohmer A, et al. Modeling gene-regulatory networks to describe cell fate transitions and predict master regulators. npj Syst Biol Appl. 2018;4:29. - PubMed
14. Guerra C, Mijimolle N, Dhawahir A, et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell. 2003;4:111-120. - PubMed
15. Mainardi S, Mijimolle N, Francoz S, Vicente-Duenas C, Sanchez-Garcia I, Barbacid M. Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma. Proc Natl Acad Sci U S A. 2014;111:255-260. - PubMed
16. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333-339. - PubMed
17. Bailey MH, Tokheim C, Porta-Pardo E, et al. Comprehensive characterization of cancer driver genes and mutations. Cell. 2018;173:371-85.e18. - PubMed
18. Armenia J, Wankowicz SAM, Liu D, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50:645-651. - PubMed
19. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306-313. - PubMed
20. Grunwald BT, Devisme A, Andrieux G, et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell. 2021;184:5577-5592. - PubMed
21. Greaves M. Evolutionary determinants of cancer. Cancer Discov. 2015;5:806-820. - PubMed
22. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168:613-628. - PubMed
23. Birkbak NJ, McGranahan N. Cancer genome evolutionary trajectories in metastasis. Cancer Cell. 2020;37:8-19. - PubMed
24. Pavlova NN, Thompson CB. The emerging hallmarks of cancer metabolism. Cell Metab. 2016;23:27-47. - PubMed
25. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194-1217. - PubMed
26. Lopez-Otin C, Kroemer G. Hallmarks of health. Cell. 2021;184:1929-1939. - PubMed
27. Mittelbrunn M, Kroemer G. Hallmarks of T cell aging. Nat Immunol. 2021;22:687-698. - PubMed
28. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674. - PubMed
29. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. - PubMed
30. Kuperstein I, Bonnet E, Nguyen HA, et al. Atlas of cancer signalling network: a systems biology resource for integrative analysis of cancer data with Google maps. Oncogenesis. 2015;4:e160. - PubMed
31. Regev A, Teichmann SA, Lander ES, et al. The human cell atlas. Elife. 2017;6:e67886. doi:10.7554/eLife.67886. PMID: 34612202 - PubMed
32. Snyder MP, Lin S, Posgai A, et al. The human body at cellular resolution: the NIH human biomolecular atlas program. Nature. 2019;574:187-192. - PubMed
33. Rajewsky N, Almouzni G, Gorski SA, et al. LifeTime and improving European healthcare through cell-based interceptive medicine. Nature. 2020;587:377-386. - PubMed
34. de Thé H, Pandolfi PP, Chen Z. Acute promyelocytic leukemia: a paradigm for oncoprotein-targeted cure. Cancer Cell. 2017;32:552-560. doi:10.1016/j.ccell.2017.10.002 - PubMed
35. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385:1447-1459. - PubMed
36. Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343-3356. - PubMed
37. Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer. 2018;18:471-484. - PubMed
38. Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature. 2012;486:346-352. doi:10.1038/nature10983 - PubMed
39. Robinson D, van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215-1228. doi:10.1016/j.cell.2015.06.053 - PubMed
40. Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. Cancer gene mutation frequencies for the US population. Nat Commun. 2021;12:5961. - PubMed
41. Farashi S, Kryza T, Clements J, Batra J. Post-GWAS in prostate cancer: from genetic association to biological contribution. Nat Rev Cancer. 2019;19:46-59. - PubMed
42. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013;153:666-677. - PubMed
43. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685-689. - PubMed
44. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012;487:239-243. doi:10.1038/nature11125 - PubMed
45. Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest. 2013;123:4918-4922. - PubMed
46. Mancuso N, Gayther S, Gusev A, et al. Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nat Commun. 2018;9:4079. - PubMed
47. Abida W, Cyrta J, Heller G, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci U S A. 2019;116:11428-11436. - PubMed
48. You S, Knudsen BS, Erho N, et al. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Res. 2016;76:4948-4958. - PubMed
49. Drake JM, Paull EO, Graham NA, et al. Phosphoproteome integration reveals patient-specific networks in prostate cancer. Cell. 2016;166:1041-1054. - PubMed
50. Boyle EA, Li YI, Pritchard JK. An expanded view of complex traits: from polygenic to omnigenic. Cell. 2017;169:1177-1186. - PubMed
51. Malysheva V, Mendoza-Parra MA, Blum M, Spivakov M, Gronemeyer H. Gene regulatory network reconstruction incorporating 3D chromosomal architecture reveals key transcription factors and DNA elements driving neural lineage commitment. bioRxiv. 2019;303842. doi:10.1101/303842 - PubMed
52. Eraslan G, Avsec Z, Gagneur J, Theis FJ. Deep learning: new computational modelling techniques for genomics. Nat Rev Genet. 2019;20:389-403. - PubMed

Publication Types

• Journal Article
• Review

Grant support

• Agence Nationale de la Recherche
• Institut National Du Cancer